<DOC>
	<DOCNO>NCT01016717</DOCNO>
	<brief_summary>To find impact two different proton-pump inhibitor ( PPIs ) ( Omeprazole Pantoprazole ) platelet function patient stable coronary artery disease ( CAD ) clopidogrel therapy .</brief_summary>
	<brief_title>Clopidogrel Proton-Pump Inhibitors Study</brief_title>
	<detailed_description>On June 19 , 2009 The European Medicines Agency ( EMEA ) issue public statement possible interaction clopidogrel ( Plavix , Sanofi-Aventis/Bristol-Myers Squibb ) proton-pump inhibitor ( PPIs ) recommend product information clopidogrel-containing medicine amend discourage concomitant use PPIs unless absolutely necessary . The UK medicine regulator , Medicines Healthcare Products Regulatory Agency ( MHRA ) , also issue advice GPs concomitant use PPI clopidogrel recommend unless consider essential , urge review prescribe PPIs next appointment patient take clopidogrel . This follow `` early communication '' issue US FDA earlier year , state PPIs might interfere effectiveness clopidogrel clinician reevaluate start continue treatment PPI patient take clopidogrel . There concern study warning base many limitation far certain whether really interaction clopidogrel PPIs . Another point uncertainty whether may difference individual PPIs , pharmacodynamic study suggest interaction omeprazole pantoprazole . The clinical evidence , however , conflict . There one clinical trial Canada suggest interaction omeprazole pantoprazole . From mechanistic view know omeprazole metabolize CYP219 enzyme , convert clopidogrel active metabolite . And pantoprazole also metabolize enzyme , also use route . Thus , primary goal current study find impact two different PPIs ( Omeprazole , Losec , Pantoprazole ) platelet function patient stable coronary artery disease ( CAD ) clopidogrel therapy . Forty patient stable CAD randomize receive either omeprazole table ( Losec , 40 mg/day , Abic Inc. , Israel ) pantoprazole table ( Controloc 40 , 40 mg/day , Nycomed , Perrigo Inc. , Israel ) 1 month ( Phase 1 ) , follow 4-week washout period , alternative treatment 1 month ( Phase 2 ) .Platelet function test assess 4 time : study phase . Following overnight fast , ECG blood test measurement platelet function , lipid , blood cell count , electrolytes , fast glucose , high-sensitivity C-reactive protein ( hs-CRP ) , perform . The blood sample , except platelet function , centrifuge immediately 15 minute 3000/min . The serum store -20° C , test end study . Blood sample platelet function assess immediately blood drawn . All blood sample evaluate laboratory operator blind patient ' clinical status PPIs allocation . All patient instruct continue take regular medication throughout study period . In addition , patient instruct add medication ( include counter medication ) record change concomitant medication throughout study period .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female ≥ 18 year ; sign informed consent 2 . Outpatient CAD patient aspirin tablet 100325 mg daily clopidogrel tablet 75 mg daily . 3 . Left ventricular ( LV ) systolic dysfunction ≥ 40 % measure within past 6 month . 4 . No change cardiac medication 2 week prior enrollment . Exclusion criterion : 1 . Presence transplant tissue organ LVAD 2 . AICD CRT CRTD patient . 3 . Acute MI , CABG , PCI within past 3 month . 4 . Congestive heart failure ( CHF ) ≥ NYHA 2 . 5 . Ejection fraction &lt; 40 % measure within past 6 month . 6 . Malignancy . 7 . Active myocarditis , cardiomyopathy . 8 . HIV infection immunodeficiency state . 9 . Chronic viral infection . 10 . Acute systemic infection require antibiotic . 11 . Chronic diarrhea malabsorption . 12 . Statin therapy initiation ≤ 3 month . 13 . Diabetes mellitus type 1 . 14 . Diabetes mellitus type 2 HbA1C &gt; 7 % 15 . Lowdensity lipoprotein cholesterol ( LDLC ) &gt; 100 mg/dL . 16 . Not statin therapy . 17 . Liver function test ( LFT ) ≥ x 3 upper limit normal ( ULN ) creatinine kinase ( CPK ) ≥ x 10 ULN . 18 . Hypo/hyper thyroidism . 19 . Liver dysfunction . 20 . Renal failure serum creatinine ≥ 2 mg/dL . 21 . Alcohol drug abuse . 22 . Refuse sign inform consent . 23 . On follow therapy : Amiodarone , coumadin , antibiotic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>clopidogrel</keyword>
	<keyword>platelet function</keyword>
	<keyword>omeprazole</keyword>
	<keyword>pantoprazole</keyword>
	<keyword>coronary disease</keyword>
</DOC>